MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2013-2288

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2013

Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.

Trabado Séverine, Maione Luigi, Bry-Gauillard Hélène, Affres Hélène, Salenave Sylvie, Sarfati Julie, Bouvattier Claire, Delemer Brigitte, Chanson Philippe, Le Bouc Yves, Brailly-Tabard Sylvie, Young Jacques

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: Insulin-like factor 3 (INSL3) is a testicular hormone secreted during fetal life, the neonatal period, and after puberty.

OBJECTIVE

To measure INSL3 levels in a large series of men with congenital hypogonadotropic hypogonadism (CHH)/ Kallmann syndrome (KS), in order to assess its diagnostic value and to investigate its regulation.

PATIENTS: We studied 281 CHH/KS patients (91 untreated, 96 receiving T, and 94 receiving combined gonadotropin therapy [human chorionic gonadotropin, hCG, and FSH]) and 72 age-matched healthy men.

METHODS

Serum INSL3 was immunoassayed with a validated RIA.

RESULTS

Mean (±SD) INSL3 levels (pg/mL) were 659 ± 279 in controls and lower (60 ± 43; P < .001) in untreated CHH/KS patients, with no overlap between the two groups, when the threshold of 250 pg/mL was used. Basal INSL3 levels were lower in both untreated CHH/KS men with cryptorchidism than in those with intrascrotal testes and in patients with testicular volumes below 4 mL. Significant positive correlations between INSL3 and both serum total T and LH levels were observed in untreated CHH/KS. Mean INSL3 levels remained low in T-treated CHH/KS patients and were significantly higher in men receiving combined hCG-FSH therapy (P < .001), but the increase was lower cryptorchid patients. FSH-hCG combination therapy or hCG monotherapy, contrary to T and FSH monotherapies, significantly increased INSL3 levels in CHH/KS.

CONCLUSIONS

INSL3 is as sensitive a marker as T for the evaluation of altered Leydig cell function in CHH/KS patients. INSL3 levels correlate with LH levels in CHH/KS men showing, together with the rise in INSL3 levels during hCG therapy, that INSL3 secretion seems not constitutively secreted during adulthood but is dependence on pituitary LH.

Для цитирования: Trabado Séverine, Maione Luigi, Bry-Gauillard Hélène, Affres Hélène, Salenave Sylvie, Sarfati Julie, Bouvattier Claire, Delemer Brigitte, Chanson Philippe, Le Bouc Yves, Brailly-Tabard Sylvie, Young Jacques. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.. The Journal of clinical endocrinology and metabolism. 2013. DOI: 10.1210/jc.2013-2288.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.